Company Overview of Novartis Institutes for BioMedical Research, Inc.
Novartis Institutes for BioMedical Research, Inc. operates as a pharmaceutical research organization. The company was incorporated in 2002 and is based in Cambridge, Massachusetts. Novartis Institutes for BioMedical Research, Inc. operates as a subsidiary of Novartis AG.
250 Massachusetts Avenue
Cambridge, MA 02139
Founded in 2002
Key Executives for Novartis Institutes for BioMedical Research, Inc.
Deputy Chief Financial Officer and Chief Financial Officer of Novartis AG
Chief Executive Officer of Novartis Animal Health
Compensation as of Fiscal Year 2015.
Novartis Institutes for BioMedical Research, Inc. Key Developments
Novartis Institutes for Biomedical Research, Inc. Initiates Phase I of PCA062
May 21 15
On May 20, 2015, Novartis Institutes for BioMedical Research, Inc. notified ImmunoGen, Inc. that it had initiated Phase I, first-in-human clinical testing of a product candidate, PCA062, utilizing antibody-drug conjugate technology. Pursuant to the license taken under 2010 Multi-Target Agreement, this start of clinical testing triggers a $5 million milestone payment to ImmunoGen.
Novartis Institutes for BioMedical Research, Inc. Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 12:15 PM
Feb 18 15
Novartis Institutes for BioMedical Research, Inc. Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 12:15 PM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Speakers: Rao Movva, Executive Director.
SomaLogic, Inc. Announces Extension of Multi-Year Collaboration Agreement with Novartis Institutes for BioMedical Research
Oct 20 14
SomaLogic, Inc. announced that Novartis has extended its multi-year research agreement for the development and application of SomaLogic's unique proteomics technology to Novartis' drug discovery and development efforts. Novartis will also take an equity position in SomaLogic under the agreement extension. Under the previous collaboration agreement, scientists at the Novartis Institutes for BioMedical Research and SomaLogic worked together to build an enhanced proprietary version of SomaLogic's SOMAscan proteomics assay for NIBR. The collaboration also included development of specific novel SOMAmer binding reagents for multiple preclinical and clinical applications in NIBR's research and development portfolio. The collaboration extension announced will enhance and expand these efforts in addition to the equity investment in SomaLogic. Other specific terms of the agreement were not disclosed. Compared to other current proteomic technologies, SomaLogic's offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. They have wide applicability in many current preclinical and clinical analytical assays, including quantitative high-content screening, targeted panels, flow cytometry, histochemistry, functional assays, and biophysical methods. SomaLogic's commercially available SOMAscan assay, which incorporates 1,129 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.
Similar Private Companies By Industry
Recent Private Companies Transactions